Grazoprevir/Elbasvir

DRUG7 trials

Sponsors

Merck Sharp & Dohme LLC, ANRS, Emerging Infectious Diseases, Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba, Kirby Institute, Tel-Aviv Sourasky Medical Center

Conditions

Acute Hepatitis CHCV, HCCHIVHepatitis C

Phase 2

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

CompletedNCT02647632

ANRS, Emerging Infectious DiseasesHepatitis C

Start: 2016-01-01End: 2017-04-01Updated: 2026-06-12

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

CompletedNCT02886624

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'BaAcute Hepatitis C, HIV

Start: 2017-05-31End: 2019-09-16Updated: 2020-01-29

Phase 3

Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

WithdrawnNCT02204475

Merck Sharp & Dohme LLCHepatitis C

Start: 2014-11-30End: 2016-09-30Updated: 2015-10-14

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

CompletedNCT02251990

Merck Sharp & Dohme LLCHepatitis C

Start: 2015-01-28End: 2017-04-10Updated: 2019-01-30

Phase 4

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs

TerminatedNCT02940691

Kirby InstituteHepatitis C

Start: 2017-05-01End: 2018-11-01Updated: 2020-03-09

Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant

King Faisal Specialist Hospital & Research CenterHepatitis C

Start: 2017-12-15End: 2018-12-31Target: 40Updated: 2017-12-02

Unknown Phase

the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.

Tel-Aviv Sourasky Medical CenterHCV, HCC

Start: 2017-05-01End: 2019-05-01Target: 20Updated: 2017-04-12

Related Papers

Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection

Journal of Addictive Diseases2022-08-034 citations

Efficacy and safety of elbasvir/grazoprevir in <scp>treatment‐naive</scp> Chinese adults with hepatitis C virus infection: A randomized trial

JGH Open2020-07-152 citations

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial.

2020-04-211 citations

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

Health Science Reports2020-03-157 citations

Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: Final results from the randomized C‐CORAL study

Journal of Gastroenterology and Hepatology2018-10-1226 citations

Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection

Hepatology Communications2018-04-0421 citations

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.

2018-01-1736 citations

Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study

Clinical Infectious Diseases2017-10-2344 citations